In the HR pathway, both germline (FDR = 1.1 × 10−4) and somatic mutations (FDR = 6.9 × 10−4) of BRCA1 were significantly associated with higher TMB in breast invasive carcinoma (BRCA) (Figure 2A), but germline variants or somatic mutations in BRCA2 showed only a non-significant trend for association with higher TMB after adjusting for multiple comparisons (FDR > 0.072, p < 0.029). This evidence concerns the gene BRCA1 and invasive breast carcinoma.